We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Industry Outlook Highlights: Mettler-Toledo International, Waters Corp, PerkinElmer and Bruker
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 22, 2021 – Today, Zacks Equity Research discusses Scientific Instruments including Mettler-Toledo International Inc. (MTD - Free Report) , Waters Corporation (WAT - Free Report) , PerkinElmer, Inc. and Bruker Corporation (BRKR - Free Report) .
The coronavirus pandemic has created unique opportunities for the Zacks Instruments - Scientific industry participants — Mettler-Toledo International, Waters, PerkinElmer and Bruker.
These companies are gaining from solid demand for coronavirus testing tools as well as rising instrument orders across the globe. Moreover, increasing spending on health care driven by an aging demography and continued innovation in the pharma and life sciences end-markets are key catalysts despite coronavirus-induced macroeconomic uncertainties.
Further, the reopening of university research laboratories as well as applied and industrial labs globally is a driving factor for the near term.
Industry Description
The Zacks Instruments - Scientific industry comprises companies offering scientific instruments, analytical tools, diagnostic solutions, precision instruments & services, and test & sensor solutions.
The primary end-markets served by the industry participants are life science research in academia, medical schools and government, pharmaceuticals and biotechnology, microbiology and diagnostics, nanotechnology, and materials science research. A few companies also serve the food and nutritional safety, biochemical, and industrial spaces.
Most of the industry participants are under stringent regulatory scrutiny worldwide. They have to adhere to the U.S. Food and Drug Administration (FDA) norms as well as rules set by other global regulatory bodies for serving highly regulated end-markets like life sciences and pharma.
3 Trends Shaping the Future of Instruments-Scientific Industry
Strong End-Market Demand: The industry is benefiting from strong end-market demand, particularly from the life science, pharmaceutical and academic markets. Increasing demand for generic drugs and biosimilars is driving growth for scientific tool and apparatus providers. Additionally, pharma companies are focusing on rapidly growing areas like proteomics and phenomics, biopharma and applied microbiology and diagnostics, and neuroscience and cell microscopy, which creates significant demand for the instruments provided by industry participants.
Aging Demography Driving Spending: Socioeconomic factors like an aging demography and increasing environmental regulations are driving demand for scientific measurement solutions. Moreover, robust worldwide healthcare spending is a major growth driver. Notably, for fiscal 2021, Congress approved roughly a 3% increase in funding for the National Institutes of Health (NIH), which now stands at $42.9 billion.
Solid Emerging Market Prospects: The industry is gaining from increasing exposure to developing economies like China and India. Prospects in China are huge as regulators are attempting to raise the country's biopharma industry to global standards.
Moreover, efforts to improve the drug development process and production quality in the country are noteworthy. These factors are resulting in strong demand for instruments. However, any undesirable turn in the recent trade spat between the United States and China will not augur well for some of the industry players.
Zacks Industry Rank Indicates Solid Prospects
The Zacks Instruments - Scientific industry is housed within the broader Zacks Computer and Technology sector. It carries a Zacks Industry Rank #37, which places it at the top 15% of more than 250 Zacks industries.
The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates solid near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.
The industry's positioning in the top 50% of the Zacks-ranked industries is a result of a positive earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are gaining confidence in this group's earnings growth potential. Since June 30, the industry's 2021 earnings estimates have increased 19.5%.
Before we present a few stocks that you may want to consider for your portfolio, let's take a look at the industry's recent stock-market performance and valuation picture.
Industry Lags Sector, Beats S&P 500
The Zacks Instruments – Scientific industry has underperformed the broader Zacks Computer and Technology sector but outperformed the S&P 500 composite over the past year.
The industry has gained 29.2% over this period compared with the S&P 500's increase of 16.3% and against the broader sector's rally of 35.2%.
Industry's Current Valuation
On the basis of forward 12-month P/E, which is a commonly used multiple for valuing scientific instrument stocks, we see that the industry is currently trading at 28.15X compared with the S&P 500's 23X and the Zacks Computer and Technology sector's 28.59X.
Over the last five years, the industry has traded as high as 28.15X, as low as 19.45X and at the median of 23.33X.
4 Scientific Instruments Providers to Watch
PerkinElmer: This Waltham, MA-headquartered company is riding on an expanding product portfolio, growing global exposure, and strengthening footprint in emerging markets like China and India.
Markedly, PerkinElemer's ChemDraw software is leading the industry. The company is gaining market share backed by solid demand for Electronic Lab Notebooks that includes cloud-based Elements SaaS Offering and enterprise E-Notebook Solutions. Moreover, solid adoption of the TIBCO Spotfire platform for scientific data analytics is a key catalyst.
Acquisitions like that of Italy-based DANI Instruments and Cisbio Bioassays have expanded this Zacks Rank #1 (Strong Buy) company's footprint in food, pharma and environmental and life sciences and diagnostics end-markets, respectively. You can see the complete list of today's Zacks #1 Rank stocks here.
PerkinElmer shares have returned 49.2% in the past year. The Zacks Consensus Estimate for its current-year earnings has been revised 0.6% north to $7.86 per share over the past 30 days.
Mettler-Toledo International: This Columbus, OH-domiciled company has returned 51.9% in the past year. This Zacks Rank #2 (Buy) company continues to see solid momentum across its Laboratory and Industrial segments. Markedly, Mettler-Toledo is the world's largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications.
Further, benefits from strategic investments in Spinnaker, marketing initiatives, field resources and product development are contributing well. Additionally, strengthening core industrial business is a major positive. Also, the company's growing momentum in China remains a tailwind.
Pricing improvement and ongoing efficiency initiatives like SternDrive are expected to help in margin expansion over the long haul.
Moreover, the Zacks Consensus Estimate for the company's current-year earnings has moved by a couple of cents north to $28.10 per share over the past 30 days.
Waters Corp.: This Milford, MA-based company is benefiting from growth in its top global pharma accounts. Solid momentum across new product lines like BioAccord and Cyclic IMS remains a positive. Further, the company's growing investments in liquid chromatography (LC), LC-MS and chemistry categories are aiding it in gaining traction in the large molecule market. Also, growing momentum across biomedical research applications is another positive.
Markedly, Waters, which is currently one of the leading players in the mass spectrometry (MS) market, has been garnering significantly from the sale of its advanced MS instruments. Further, increasing regulation around food safety and quality, strict conditions for food testing, and environmental and fine chemical applications bode well for the company's prospects. Additionally, strong execution of the company's cost-cutting strategies remains a tailwind.
Additionally, the consensus mark for this Zacks Rank #3 (Hold) company's current-year earnings has moved 0.7% north to $9.15 per share over the past 30 days. Shares are up 11.3% in the past year.
Bruker: This Billerica, MA-headquartered company is well-poised to grow in the proteomics and spatial-omics fields. This Zacks Rank #3 company benefits from strong prospects in the Nuclear Magnetic Resonance (NMR) industry, MALDI Biotyper and preclinical imaging (PCI) market.
Markedly, Bruker's BioSpin products, which have specific application in structural proteomics, drug discovery, research and food and materials science fields, provide customers with the ability to ascertain the structure, dynamics, and function of specific molecules, such as proteins, as well as characterize and determine the composition of mixtures.
Moreover, demand for the MALDI Biotyper is increasing in applied markets, specifically for food, feed and beverage. Additionally, Bruker offers advanced PCI solutions for a broad spectrum of application fields, such as cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. Moreover, this division is experiencing increasing customer demand for higher-strength pre-clinical magnetic resonance imaging systems.
Notably, the Zacks Consensus Estimate for 2021 earnings has moved up by a penny to $1.72 per share in the past 30 days. The stock has increased 14.5% on a year-to-date basis.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it's expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks' just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Industry Outlook Highlights: Mettler-Toledo International, Waters Corp, PerkinElmer and Bruker
For Immediate Release
Chicago, IL – January 22, 2021 – Today, Zacks Equity Research discusses Scientific Instruments including Mettler-Toledo International Inc. (MTD - Free Report) , Waters Corporation (WAT - Free Report) , PerkinElmer, Inc. and Bruker Corporation (BRKR - Free Report) .
Link: https://www.zacks.com/commentary/1249835/4-stocks-to-watch-on-rising-demand-for-scientific-instruments
The coronavirus pandemic has created unique opportunities for the Zacks Instruments - Scientific industry participants — Mettler-Toledo International, Waters, PerkinElmer and Bruker.
These companies are gaining from solid demand for coronavirus testing tools as well as rising instrument orders across the globe. Moreover, increasing spending on health care driven by an aging demography and continued innovation in the pharma and life sciences end-markets are key catalysts despite coronavirus-induced macroeconomic uncertainties.
Further, the reopening of university research laboratories as well as applied and industrial labs globally is a driving factor for the near term.
Industry Description
The Zacks Instruments - Scientific industry comprises companies offering scientific instruments, analytical tools, diagnostic solutions, precision instruments & services, and test & sensor solutions.
The primary end-markets served by the industry participants are life science research in academia, medical schools and government, pharmaceuticals and biotechnology, microbiology and diagnostics, nanotechnology, and materials science research. A few companies also serve the food and nutritional safety, biochemical, and industrial spaces.
Most of the industry participants are under stringent regulatory scrutiny worldwide. They have to adhere to the U.S. Food and Drug Administration (FDA) norms as well as rules set by other global regulatory bodies for serving highly regulated end-markets like life sciences and pharma.
3 Trends Shaping the Future of Instruments-Scientific Industry
Strong End-Market Demand: The industry is benefiting from strong end-market demand, particularly from the life science, pharmaceutical and academic markets. Increasing demand for generic drugs and biosimilars is driving growth for scientific tool and apparatus providers. Additionally, pharma companies are focusing on rapidly growing areas like proteomics and phenomics, biopharma and applied microbiology and diagnostics, and neuroscience and cell microscopy, which creates significant demand for the instruments provided by industry participants.
Aging Demography Driving Spending: Socioeconomic factors like an aging demography and increasing environmental regulations are driving demand for scientific measurement solutions. Moreover, robust worldwide healthcare spending is a major growth driver. Notably, for fiscal 2021, Congress approved roughly a 3% increase in funding for the National Institutes of Health (NIH), which now stands at $42.9 billion.
Solid Emerging Market Prospects: The industry is gaining from increasing exposure to developing economies like China and India. Prospects in China are huge as regulators are attempting to raise the country's biopharma industry to global standards.
Moreover, efforts to improve the drug development process and production quality in the country are noteworthy. These factors are resulting in strong demand for instruments. However, any undesirable turn in the recent trade spat between the United States and China will not augur well for some of the industry players.
Zacks Industry Rank Indicates Solid Prospects
The Zacks Instruments - Scientific industry is housed within the broader Zacks Computer and Technology sector. It carries a Zacks Industry Rank #37, which places it at the top 15% of more than 250 Zacks industries.
The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates solid near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.
The industry's positioning in the top 50% of the Zacks-ranked industries is a result of a positive earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are gaining confidence in this group's earnings growth potential. Since June 30, the industry's 2021 earnings estimates have increased 19.5%.
Before we present a few stocks that you may want to consider for your portfolio, let's take a look at the industry's recent stock-market performance and valuation picture.
Industry Lags Sector, Beats S&P 500
The Zacks Instruments – Scientific industry has underperformed the broader Zacks Computer and Technology sector but outperformed the S&P 500 composite over the past year.
The industry has gained 29.2% over this period compared with the S&P 500's increase of 16.3% and against the broader sector's rally of 35.2%.
Industry's Current Valuation
On the basis of forward 12-month P/E, which is a commonly used multiple for valuing scientific instrument stocks, we see that the industry is currently trading at 28.15X compared with the S&P 500's 23X and the Zacks Computer and Technology sector's 28.59X.
Over the last five years, the industry has traded as high as 28.15X, as low as 19.45X and at the median of 23.33X.
4 Scientific Instruments Providers to Watch
PerkinElmer: This Waltham, MA-headquartered company is riding on an expanding product portfolio, growing global exposure, and strengthening footprint in emerging markets like China and India.
Markedly, PerkinElemer's ChemDraw software is leading the industry. The company is gaining market share backed by solid demand for Electronic Lab Notebooks that includes cloud-based Elements SaaS Offering and enterprise E-Notebook Solutions. Moreover, solid adoption of the TIBCO Spotfire platform for scientific data analytics is a key catalyst.
Acquisitions like that of Italy-based DANI Instruments and Cisbio Bioassays have expanded this Zacks Rank #1 (Strong Buy) company's footprint in food, pharma and environmental and life sciences and diagnostics end-markets, respectively. You can see the complete list of today's Zacks #1 Rank stocks here.
PerkinElmer shares have returned 49.2% in the past year. The Zacks Consensus Estimate for its current-year earnings has been revised 0.6% north to $7.86 per share over the past 30 days.
Mettler-Toledo International: This Columbus, OH-domiciled company has returned 51.9% in the past year. This Zacks Rank #2 (Buy) company continues to see solid momentum across its Laboratory and Industrial segments. Markedly, Mettler-Toledo is the world's largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications.
Further, benefits from strategic investments in Spinnaker, marketing initiatives, field resources and product development are contributing well. Additionally, strengthening core industrial business is a major positive. Also, the company's growing momentum in China remains a tailwind.
Pricing improvement and ongoing efficiency initiatives like SternDrive are expected to help in margin expansion over the long haul.
Moreover, the Zacks Consensus Estimate for the company's current-year earnings has moved by a couple of cents north to $28.10 per share over the past 30 days.
Waters Corp.: This Milford, MA-based company is benefiting from growth in its top global pharma accounts. Solid momentum across new product lines like BioAccord and Cyclic IMS remains a positive. Further, the company's growing investments in liquid chromatography (LC), LC-MS and chemistry categories are aiding it in gaining traction in the large molecule market. Also, growing momentum across biomedical research applications is another positive.
Markedly, Waters, which is currently one of the leading players in the mass spectrometry (MS) market, has been garnering significantly from the sale of its advanced MS instruments. Further, increasing regulation around food safety and quality, strict conditions for food testing, and environmental and fine chemical applications bode well for the company's prospects. Additionally, strong execution of the company's cost-cutting strategies remains a tailwind.
Additionally, the consensus mark for this Zacks Rank #3 (Hold) company's current-year earnings has moved 0.7% north to $9.15 per share over the past 30 days. Shares are up 11.3% in the past year.
Bruker: This Billerica, MA-headquartered company is well-poised to grow in the proteomics and spatial-omics fields. This Zacks Rank #3 company benefits from strong prospects in the Nuclear Magnetic Resonance (NMR) industry, MALDI Biotyper and preclinical imaging (PCI) market.
Markedly, Bruker's BioSpin products, which have specific application in structural proteomics, drug discovery, research and food and materials science fields, provide customers with the ability to ascertain the structure, dynamics, and function of specific molecules, such as proteins, as well as characterize and determine the composition of mixtures.
Moreover, demand for the MALDI Biotyper is increasing in applied markets, specifically for food, feed and beverage. Additionally, Bruker offers advanced PCI solutions for a broad spectrum of application fields, such as cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. Moreover, this division is experiencing increasing customer demand for higher-strength pre-clinical magnetic resonance imaging systems.
Notably, the Zacks Consensus Estimate for 2021 earnings has moved up by a penny to $1.72 per share in the past 30 days. The stock has increased 14.5% on a year-to-date basis.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it's expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks' just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.